Labcorp Holdings Inc. (lh)

LH — Company Overview

Labcorp Holdings Inc. (LH) trades on NYQ as part of the Healthcare peer group (Diagnostics & Research).

LH — Business Description

LH represents a Diagnostics & Research business in the Healthcare segment. Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmac…

Official website: https://www.labcorp.com.

LH — Investment Thesis

At a high level, LH offers exposure to Healthcare with metrics outlined below from public market data.

• Revenue is expanding at roughly 5.8% year-over-year (public data).
• Trailing P/E of 25.87× sits in a moderate band relative to high-growth peers.
• Forward P/E (15.32×) is below trailing P/E — earnings may be expected to improve.
• Dividend yield near 0.9% adds an income component to total return.
• Equity market capitalization is approximately $24.65B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

LH — Financial Health

Key financial health indicators for Labcorp Holdings Inc. are derived exclusively from public data — no proprietary estimates.

Profit margin near 7.0% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $892.05M supports balance-sheet flexibility.

LH — Growth Outlook

Growth outlook for Labcorp Holdings Inc. (LH) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 5.8% suggests steady but measured expansion.
• Earnings growth of 28.2% year-over-year supports improving profitability.
• Price is 11.1% below the 52-week high.
• Shares trade 24.3% above the 52-week low — limited rebound so far.

LH — Competitive Position

Labcorp Holdings Inc. (LH) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Diagnostics & Research.
• Market capitalization of $24.65B places LH among large-cap peers.
• Gross margin of 28.9% should be benchmarked against direct competitors.

LH — Summary

Labcorp Holdings Inc. (LH) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NYQ. Last price $303.98 with market cap $24.65B. Trailing P/E 25.87×. Revenue grew 5.8% year-over-year per public data. Notable strengths include revenue growth of 5.8% year-over-year. Premium Terminal tools for Labcorp Holdings Inc. add ownership analytics, news, and richer estimate history beyond this public summary.